High Glucose Enhances DPP-4 Inhibitor-Associated Hippo–YAP/TAZ Modulation and Apoptotic Signaling in Pancreatic Cancer Cells

Pancreatic cancer is a relentless disease, often diagnosed only after it has spread, leaving patients with very few treatment options. A significant portion of these patients also live with diabetes, a condition where the body struggles to manage sugar, leading to high levels of glucose in the blood. Scientists have long suspected that this excess sugar does more than just damage blood vessels; it may actively feed the cancer, helping it grow and survive. To treat diabetes, doctors frequently prescribe a class of drugs called DPP-4 inhibitors. These medications help lower blood sugar by blocking a specific enzyme that breaks down natural hormones. However, a lingering question remains: if these drugs are circulating in the blood of a person with both diabetes and pancreatic cancer, do they simply lower sugar, or do they interact with the cancer cells themselves? Does the high-sugar environment change how the cancer cells react to the medicine?

To answer this, researchers at The Catholic University of Korea set out to watch what happens inside pancreatic cancer cells when they are exposed to these common diabetes drugs under different sugar conditions. They used a specific type of pancreatic cancer cell, known as MIA PaCa-2, and grew them in a laboratory dish. They created two distinct environments for these cells: one with a normal amount of sugar and another with a high amount, mimicking the conditions found in uncontrolled diabetes. Into these environments, they introduced two different DPP-4 inhibitors, evogliptin and sitagliptin, at concentrations that were much higher than what a human patient would typically have in their bloodstream. The goal was not to test a new cure for patients, but to understand the basic mechanics of how the cells behave when sugar and drugs collide.

The researchers first looked at whether the drugs could stop the cancer cells from multiplying. In the normal sugar environment, the drugs did slow the cells down, but the effect was modest. When the sugar levels were high, the cells initially grew faster, showing that the extra fuel made them more vigorous. However, when the drugs were added to this high-sugar mix, the cancer cells died off much more quickly and in greater numbers than they did in the normal sugar environment. The drugs were far more effective at killing the cells when those cells were swimming in high glucose. This suggested that the high-sugar environment, rather than protecting the cancer, actually made the cells more vulnerable to the drug's lethal effects.

Digging deeper, the team examined the internal machinery of the cells to understand why this happened. They focused on a specific pathway inside the cell that acts like a switch for growth and survival, known as the Hippo-YAP/TAZ pathway. This system helps cells decide when to divide and when to stop. The researchers watched how the key components of this system moved around inside the cell over time. Shortly after adding the drugs, they saw a temporary surge in the number of cells where the growth-promoting protein, YAP, moved into the nucleus, the cell's control center. This was a brief moment of activity. However, as time passed, the cell's internal brakes were firmly engaged. The levels of a "stop" signal increased, and the growth protein was chemically tagged to keep it out of the nucleus. This tagging process is what usually tells a cell to stop growing or to start dying.

The study also revealed that the drugs triggered the cell's self-destruction program, known as apoptosis. The researchers found clear signs that the cells were dismantling themselves, with specific proteins breaking apart in a way that signals the end of the cell's life. Interestingly, while some signals that usually prevent cell death increased alongside the death signals, the overall result was a strong push toward the cell's demise. To confirm that the Hippo-YAP/TAZ pathway was indeed the critical link, the researchers used a technique to temporarily silence the genes for YAP and its partner, TAZ. When these genes were turned off, the cells changed their behavior, and the drugs lost much of their ability to kill the cells. This proved that the presence and status of YAP and TAZ were essential for the drugs to work as they did.

Despite these clear findings in the lab, the researchers were careful to define the limits of their work. The concentrations of the drugs they used were hundreds of times higher than what a person would have in their blood after taking a standard pill. Because of this, they could not claim that these drugs would work as a treatment for pancreatic cancer in humans. Furthermore, they did not prove that the drugs were acting specifically on the DPP-4 enzyme itself; the effects might have been caused by the drugs interacting with other parts of the cell. The study was also limited to a single type of cancer cell grown in a dish, without the complex environment of a living body, which includes blood vessels and immune cells.

Ultimately, this research provides a detailed map of a specific biological interaction. It shows that high glucose levels can change how pancreatic cancer cells respond to diabetes medications, making them more susceptible to cell death through a specific internal signaling pathway. While the study does not offer a new treatment, it generates a new hypothesis: that the metabolic state of a patient, specifically their blood sugar levels, might influence how their cancer cells react to certain drugs. This insight suggests that future research should look more closely at how sugar availability and these common medications interact, potentially opening new doors for understanding the complex relationship between diabetes and cancer.